Literature DB >> 14969569

Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Michael A Veltri1, Alicia M Neu, Barbara A Fivush, Rulan S Parekh, Susan L Furth.   

Abstract

Chronic renal failure is, fortunately, an unusual occurrence in children; however, many children with various underlying illnesses develop acute renal failure, and transiently require renal replacement therapy - peritoneal dialysis, intermittent hemodialysis (IHD), or continuous renal replacement therapy (CRRT). As children with acute and chronic renal failure often have multiple comorbid conditions requiring drug therapy, generalists, intensivists, nephrologists, and pharmacists need to be aware of the issues surrounding the management of drug therapy in pediatric patients undergoing renal replacement therapy. This article summarizes the pharmacokinetics and dosing of many drugs commonly prescribed for pediatric patients, and focuses on the management of drug therapy in pediatric patients undergoing IHD and CRRT in the intensive care unit setting. Peritoneal dialysis is not considered in this review. Finally, a summary table with recommended initial dosages for drugs commonly encountered in pediatric patients requiring IHD or CRRT is presented.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14969569     DOI: 10.2165/00148581-200406010-00004

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  97 in total

1.  Amikacin pharmacokinetics during continuous veno-venous hemofiltration.

Authors:  R Robert; E Rochard; F Malin; S Bouquet
Journal:  Crit Care Med       Date:  1991-04       Impact factor: 7.598

Review 2.  Pharmacokinetics of cefotaxime in dialysis patients.

Authors:  K Andrassy
Journal:  Diagn Microbiol Infect Dis       Date:  1995 May-Jun       Impact factor: 2.803

3.  Hemodialysis removal of acyclovir.

Authors:  J B Leikin; L Shicker; J Orlowski; A T Blair; K McAllister
Journal:  Vet Hum Toxicol       Date:  1995-06

4.  Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.

Authors:  M Del Rio; G H McCracken; J D Nelson; D Chrane; S Shelton
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

5.  Single dose pharmacokinetics of linezolid in infants and children.

Authors:  G L Kearns; S M Abdel-Rahman; J L Blumer; M D Reed; L P James; R F Jacobs; J A Bradley; I R Welshman; G L Jungbluth; D J Stalker
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

6.  Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates.

Authors:  S Brunet; M Leblanc; D Geadah; D Parent; S Courteau; J Cardinal
Journal:  Am J Kidney Dis       Date:  1999-09       Impact factor: 8.860

7.  Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis.

Authors:  S P Davies; L F Lacey; W J Kox; E A Brown
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

Review 8.  Cefotetan. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A Ward; D M Richards
Journal:  Drugs       Date:  1985-11       Impact factor: 9.546

9.  Cefoxitin in newborn infants. A clinical and pharmacokinetic study.

Authors:  M B Regazzi; G Chirico; D Cristiani; G Rondini; R Rondanelli
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients.

Authors:  E Keller; J Böhler; A Busse-Grawitz; P Reetze-Bonorden; B Krumme; P Schollmeyer
Journal:  Clin Nephrol       Date:  1995-01       Impact factor: 0.975

View more
  7 in total

1.  Pediatric acute kidney injury: it's time for real progress.

Authors:  Stuart L Goldstein
Journal:  Pediatr Nephrol       Date:  2006-05-30       Impact factor: 3.714

Review 2.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

3.  Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.

Authors:  Samuel Dubinsky; Kevin Watt; Steven Saleeb; Bilal Ahmed; Caitlin Carter; Cindy H T Yeung; Andrea Edginton
Journal:  Clin Pharmacokinet       Date:  2021-11-30       Impact factor: 6.447

4.  Antimicrobial Dosing Recommendations in Pediatric Continuous Renal Replacement Therapy: A Critical Appraisal of Current Evidence.

Authors:  Gideon Stitt; Samuel Dubinsky; Andrea Edginton; Yuan-Shung V Huang; Athena F Zuppa; Kevin Watt; Kevin Downes
Journal:  Front Pediatr       Date:  2022-05-12       Impact factor: 3.569

5.  Pilot Study of the Pharmacokinetics of Cefotaxime in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy.

Authors:  Joost B Koedijk; Corinne G H Valk-Swinkels; Tom A Rijpstra; Daan J Touw; Paul G H Mulder; Peter H J van der Voort; Nils E van 't Veer; Nardo J M van der Meer
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 6.  Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children.

Authors:  Frederique Rodieux; Melanie Wilbaux; Johannes N van den Anker; Marc Pfister
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

7.  Anti-infective Medicines Use in Children and Neonates With Pre-existing Kidney Dysfunction: A Systematic Review.

Authors:  Chiara Minotti; Elisa Barbieri; Denis Doni; Cristina Impieri; Carlo Giaquinto; Daniele Donà
Journal:  Front Pediatr       Date:  2022-04-26       Impact factor: 3.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.